Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA wild-type PTEN pos |
Therapy | Cetuximab + Cisplatin |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA wild-type PTEN pos | head and neck squamous cell carcinoma | predicted - sensitive | Cetuximab + Cisplatin | Clinical Study - Cohort | Actionable | In a clinical study, combination of Erbitux (cetuximab) with Platinol (cisplatin) tended to improve progression-free survival compared to placebo in PTEN-expressing, PIK3CA wild-type head and neck squamous cell carcinoma patients (HR=0.54, p=0.0502) by multivariable analysis, but not in PTEN null or PIK3CA mutated patients (HR=0.76, p=0.54) (PMID: 30926065). | 30926065 |
PubMed Id | Reference Title | Details |
---|---|---|
(30926065) | PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. | Full reference... |